9-Phenanthrol and flufenamic acid inhibit calcium oscillations in HL-1 mouse cardiomyocytes

Department of Biomedical Sciences, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA.
Cell calcium (Impact Factor: 3.51). 07/2013; 54(3). DOI: 10.1016/j.ceca.2013.06.003
Source: PubMed


It is well established that intracellular calcium ([Ca(2+)]i) controls the inotropic state of the myocardium, and evidence mounts that a "Ca(2+) clock" controls the chronotropic state of the heart. Recent findings describe a calcium-activated nonselective cation channel (NSCCa) in various cardiac preparations sharing hallmark characteristics of the transient receptor potential melastatin 4 (TRPM4). TRPM4 is functionally expressed throughout the heart and has been implicated as a NSCCa that mediates membrane depolarization. However, the functional significance of TRPM4 in regards to Ca(2+) signaling and its effects on cellular excitability and pacemaker function remains inconclusive. Here, we show by Fura2 Ca-imaging that pharmacological inhibition of TRPM4 in HL-1 mouse cardiac myocytes by 9-phenanthrol (10μM) and flufenamic acid (10 and 100μM) decreases Ca(2+) oscillations followed by an overall increase in [Ca(2+)]i. The latter occurs also in HL-1 cells in Ca(2+)-free solution and after depletion of sarcoplasmic reticulum Ca(2+) with thapsigargin (10μM). These pharmacologic agents also depolarize HL-1 cell mitochondrial membrane potential. Furthermore, by on-cell voltage clamp we show that 9-phenanthrol reversibly inhibits membrane current; by fluorescence immunohistochemistry we demonstrate that HL-1 cells display punctate surface labeling with TRPM4 antibody; and by immunoblotting using this antibody we show these cells express a 130-150kDa protein, as expected for TRPM4. We conclude that 9-phenanthrol inhibits TRPM4 ion channels in HL-1 cells, which in turn decreases Ca(2+) oscillations followed by a compensatory increase in [Ca(2+)]i from an intracellular store other than the sarcoplasmic reticulum. We speculate that the most likely source is the mitochondrion.

11 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The transient receptor potential melastatin 4 (TRPM4) channel is expressed in sino-atrial node but its physiological roles in this tissue with cardiac pacemaker properties remains unknown. This Ca(2+)-activated non-selective cation channel (NSCCa) induces cell depolarization at negative potentials. It is implicated in burst generation in neurons and participates in the induction of ectopic beating in cardiac ventricular preparations submitted to hypoxia/reoxygenation. Accordingly, TRPM4 may participate in action potential (AP) triggering in sino-atrial node. This study investigates the influence of TRPM4 on spontaneous heart beating. Spontaneous APs were recorded using intracellular microelectrodes in mouse, rat and rabbit isolated right atria. In the spontaneously beating mouse atrium, superfusion of the TRPM4 specific inhibitor 9-phenanthrol produced a concentration-dependant reduction in AP rate (maximal reduction = 62% that of control; EC50 = 8x10(-6) mol.L(-1)) without affecting other AP parameters. These effects were absent in Trpm4(-/-) mice. 9-phenanthrol exerted a rate-dependent reduction with a higher effect at low rates. Similar results were obtained in rat. Moreover, application of 9-phenanthrol produced a reduction in diastolic depolarization slope in rabbit sinus node pacemaker cells. These data showed that TRPM4 modulates beating rate. Pacemaker activity in sino-atrial node results from the slow diastolic depolarization slope due to the 'funny' current, the Na/Ca exchange and a Ca(2+)-activated non-selective cation current, which can be attributable in part to TRPM4 that may act against bradycardia.
    Heart rhythm: the official journal of the Heart Rhythm Society 08/2013; 10(11). DOI:10.1016/j.hrthm.2013.08.014 · 5.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The phenanthrene-derivative 9-phenanthrol is a recently identified inhibitor of the TRPM4 Ca(2+) -activated non-selective cation channel whose mechanism of action remains to be determined. Subsequent studies performed on other ion channels confirm the specificity of the drug for TRPM4. In addition, 9-phenanthrol modulates a variety of physiological processes through TRPM4 current inhibition and thus exerts beneficial effects in several pathological conditions. 9-phenanthrol modulates smooth muscle contraction in bladder and cerebral arteries, impacts spontaneous activity in neurons and heart, and reduces lipopolysaccharide-induced cell death. Among promising potential applications, 9-phenanthrol exerts cardioprotective effects against ischemia-reperfusion injuries and reduces ischemic stroke injuries. In addition to reviewing the biophysical effects of 9-phenanthrol, here we present information about its appropriate use in physiological studies and possible clinical applications.
    British Journal of Pharmacology 01/2014; 171(7). DOI:10.1111/bph.12582 · 4.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The non-selective Transient Receptor Potential Melastatin 4 (TRPM4) cation channel is abundantly expressed in cardiac cells, being involved in several aspects of cardiac rhythmicity, including cardiac conduction, pace making and action-potential repolarization. Dominantly inherited mutations in the TRPM4 gene are associated with the cardiac bundle-branch disorder progressive familial heart block type I (PFHBI) and isolated cardiac conduction disease (ICCD) giving rise to atrio-ventricular conduction block (AVB), right bundle branch block, bradycardia, and the Brugada syndrome. The mutant phenotypes closely resemble those associated with mutations in the SCN5A gene, encoding the voltage-gated Na(+) channel NaV1.5. These observations and the unexpected partnership with sulfonylurea-receptors (SURs) makes the TRPM4 channel a promising novel target for treatment of cardiac disorders.
    Current Opinion in Pharmacology 04/2014; 15C(1):68-73. DOI:10.1016/j.coph.2013.12.003 · 4.60 Impact Factor
Show more